Cargando…

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review

SIMPLE SUMMARY: Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. Despite recent improvements in adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer, estimating the risk of relapse of breast cancer on an individual basis is...

Descripción completa

Detalles Bibliográficos
Autores principales: Garutti, Mattia, Griguolo, Gaia, Botticelli, Andrea, Buzzatti, Giulia, De Angelis, Carmine, Gerratana, Lorenzo, Molinelli, Chiara, Adamo, Vincenzo, Bianchini, Giampaolo, Biganzoli, Laura, Curigliano, Giuseppe, De Laurentiis, Michelino, Fabi, Alessandra, Frassoldati, Antonio, Gennari, Alessandra, Marchiò, Caterina, Perrone, Francesco, Viale, Giuseppe, Zamagni, Claudio, Zambelli, Alberto, Del Mastro, Lucia, De Placido, Sabino, Guarneri, Valentina, Marchetti, Paolo, Puglisi, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029479/
https://www.ncbi.nlm.nih.gov/pubmed/35454806
http://dx.doi.org/10.3390/cancers14081898
_version_ 1784691888305995776
author Garutti, Mattia
Griguolo, Gaia
Botticelli, Andrea
Buzzatti, Giulia
De Angelis, Carmine
Gerratana, Lorenzo
Molinelli, Chiara
Adamo, Vincenzo
Bianchini, Giampaolo
Biganzoli, Laura
Curigliano, Giuseppe
De Laurentiis, Michelino
Fabi, Alessandra
Frassoldati, Antonio
Gennari, Alessandra
Marchiò, Caterina
Perrone, Francesco
Viale, Giuseppe
Zamagni, Claudio
Zambelli, Alberto
Del Mastro, Lucia
De Placido, Sabino
Guarneri, Valentina
Marchetti, Paolo
Puglisi, Fabio
author_facet Garutti, Mattia
Griguolo, Gaia
Botticelli, Andrea
Buzzatti, Giulia
De Angelis, Carmine
Gerratana, Lorenzo
Molinelli, Chiara
Adamo, Vincenzo
Bianchini, Giampaolo
Biganzoli, Laura
Curigliano, Giuseppe
De Laurentiis, Michelino
Fabi, Alessandra
Frassoldati, Antonio
Gennari, Alessandra
Marchiò, Caterina
Perrone, Francesco
Viale, Giuseppe
Zamagni, Claudio
Zambelli, Alberto
Del Mastro, Lucia
De Placido, Sabino
Guarneri, Valentina
Marchetti, Paolo
Puglisi, Fabio
author_sort Garutti, Mattia
collection PubMed
description SIMPLE SUMMARY: Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. Despite recent improvements in adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (high risk definition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormone-positive/HER2−negative early breast cancer relapse. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers. ABSTRACT: Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormone-positive/HER2−negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers.
format Online
Article
Text
id pubmed-9029479
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90294792022-04-23 Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review Garutti, Mattia Griguolo, Gaia Botticelli, Andrea Buzzatti, Giulia De Angelis, Carmine Gerratana, Lorenzo Molinelli, Chiara Adamo, Vincenzo Bianchini, Giampaolo Biganzoli, Laura Curigliano, Giuseppe De Laurentiis, Michelino Fabi, Alessandra Frassoldati, Antonio Gennari, Alessandra Marchiò, Caterina Perrone, Francesco Viale, Giuseppe Zamagni, Claudio Zambelli, Alberto Del Mastro, Lucia De Placido, Sabino Guarneri, Valentina Marchetti, Paolo Puglisi, Fabio Cancers (Basel) Review SIMPLE SUMMARY: Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. Despite recent improvements in adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (high risk definition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormone-positive/HER2−negative early breast cancer relapse. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers. ABSTRACT: Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormone-positive/HER2−negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers. MDPI 2022-04-09 /pmc/articles/PMC9029479/ /pubmed/35454806 http://dx.doi.org/10.3390/cancers14081898 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Garutti, Mattia
Griguolo, Gaia
Botticelli, Andrea
Buzzatti, Giulia
De Angelis, Carmine
Gerratana, Lorenzo
Molinelli, Chiara
Adamo, Vincenzo
Bianchini, Giampaolo
Biganzoli, Laura
Curigliano, Giuseppe
De Laurentiis, Michelino
Fabi, Alessandra
Frassoldati, Antonio
Gennari, Alessandra
Marchiò, Caterina
Perrone, Francesco
Viale, Giuseppe
Zamagni, Claudio
Zambelli, Alberto
Del Mastro, Lucia
De Placido, Sabino
Guarneri, Valentina
Marchetti, Paolo
Puglisi, Fabio
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
title Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
title_full Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
title_fullStr Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
title_full_unstemmed Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
title_short Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
title_sort definition of high-risk early hormone-positive her2−negative breast cancer: a consensus review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029479/
https://www.ncbi.nlm.nih.gov/pubmed/35454806
http://dx.doi.org/10.3390/cancers14081898
work_keys_str_mv AT garuttimattia definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT griguologaia definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT botticelliandrea definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT buzzattigiulia definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT deangeliscarmine definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT gerratanalorenzo definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT molinellichiara definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT adamovincenzo definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT bianchinigiampaolo definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT biganzolilaura definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT curiglianogiuseppe definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT delaurentiismichelino definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT fabialessandra definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT frassoldatiantonio definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT gennarialessandra definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT marchiocaterina definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT perronefrancesco definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT vialegiuseppe definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT zamagniclaudio definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT zambellialberto definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT delmastrolucia definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT deplacidosabino definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT guarnerivalentina definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT marchettipaolo definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview
AT puglisifabio definitionofhighriskearlyhormonepositiveher2negativebreastcanceraconsensusreview